Cargando…
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606985/ https://www.ncbi.nlm.nih.gov/pubmed/26362631 http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016567 |
_version_ | 1782395449173344256 |
---|---|
author | Fontana, Marianna Pica, Silvia Reant, Patricia Abdel-Gadir, Amna Treibel, Thomas A. Banypersad, Sanjay M. Maestrini, Viviana Barcella, William Rosmini, Stefania Bulluck, Heerajnarain Sayed, Rabya H. Patel, Ketna Mamhood, Shameem Bucciarelli-Ducci, Chiara Whelan, Carol J. Herrey, Anna S. Lachmann, Helen J. Wechalekar, Ashutosh D. Manisty, Charlotte H. Schelbert, Eric B. Kellman, Peter Gillmore, Julian D. Hawkins, Philip N. Moon, James C. |
author_facet | Fontana, Marianna Pica, Silvia Reant, Patricia Abdel-Gadir, Amna Treibel, Thomas A. Banypersad, Sanjay M. Maestrini, Viviana Barcella, William Rosmini, Stefania Bulluck, Heerajnarain Sayed, Rabya H. Patel, Ketna Mamhood, Shameem Bucciarelli-Ducci, Chiara Whelan, Carol J. Herrey, Anna S. Lachmann, Helen J. Wechalekar, Ashutosh D. Manisty, Charlotte H. Schelbert, Eric B. Kellman, Peter Gillmore, Julian D. Hawkins, Philip N. Moon, James C. |
author_sort | Fontana, Marianna |
collection | PubMed |
description | The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk is unknown. METHODS AND RESULTS—: Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance. Subjects were followed up for a mean of 24±13 months. LGE was performed with phase-sensitive inversion recovery (PSIR) and without (magnitude only). These were compared with extracellular volume measured with T1 mapping. PSIR was superior to magnitude-only inversion recovery LGE because PSIR always nulled the tissue (blood or myocardium) with the longest T1 (least gadolinium). LGE was classified into 3 patterns: none, subendocardial, and transmural, which were associated with increasing amyloid burden as defined by extracellular volume (P<0.0001), with transitions from none to subendocardial LGE at an extracellular volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 0.55 (AL) and 0.47 to 0.59 (ATTR). Sixty-seven patients (27%) died. Transmural LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 2.1–13.7; P<0.0001) and remained independent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke volume index, E/E′, and left ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3–13.1; P<0.05). CONCLUSIONS—: There is a continuum of cardiac involvement in systemic AL and ATTR amyloidosis. Transmural LGE is determined reliably by PSIR and represents advanced cardiac amyloidosis. The PSIR technique provides incremental information on outcome even after adjustment for known prognostic factors. |
format | Online Article Text |
id | pubmed-4606985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-46069852015-10-29 Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis Fontana, Marianna Pica, Silvia Reant, Patricia Abdel-Gadir, Amna Treibel, Thomas A. Banypersad, Sanjay M. Maestrini, Viviana Barcella, William Rosmini, Stefania Bulluck, Heerajnarain Sayed, Rabya H. Patel, Ketna Mamhood, Shameem Bucciarelli-Ducci, Chiara Whelan, Carol J. Herrey, Anna S. Lachmann, Helen J. Wechalekar, Ashutosh D. Manisty, Charlotte H. Schelbert, Eric B. Kellman, Peter Gillmore, Julian D. Hawkins, Philip N. Moon, James C. Circulation Original Articles The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk is unknown. METHODS AND RESULTS—: Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance. Subjects were followed up for a mean of 24±13 months. LGE was performed with phase-sensitive inversion recovery (PSIR) and without (magnitude only). These were compared with extracellular volume measured with T1 mapping. PSIR was superior to magnitude-only inversion recovery LGE because PSIR always nulled the tissue (blood or myocardium) with the longest T1 (least gadolinium). LGE was classified into 3 patterns: none, subendocardial, and transmural, which were associated with increasing amyloid burden as defined by extracellular volume (P<0.0001), with transitions from none to subendocardial LGE at an extracellular volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 0.55 (AL) and 0.47 to 0.59 (ATTR). Sixty-seven patients (27%) died. Transmural LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 2.1–13.7; P<0.0001) and remained independent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke volume index, E/E′, and left ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3–13.1; P<0.05). CONCLUSIONS—: There is a continuum of cardiac involvement in systemic AL and ATTR amyloidosis. Transmural LGE is determined reliably by PSIR and represents advanced cardiac amyloidosis. The PSIR technique provides incremental information on outcome even after adjustment for known prognostic factors. Lippincott Williams & Wilkins 2015-10-20 2015-10-19 /pmc/articles/PMC4606985/ /pubmed/26362631 http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016567 Text en © 2015 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. |
spellingShingle | Original Articles Fontana, Marianna Pica, Silvia Reant, Patricia Abdel-Gadir, Amna Treibel, Thomas A. Banypersad, Sanjay M. Maestrini, Viviana Barcella, William Rosmini, Stefania Bulluck, Heerajnarain Sayed, Rabya H. Patel, Ketna Mamhood, Shameem Bucciarelli-Ducci, Chiara Whelan, Carol J. Herrey, Anna S. Lachmann, Helen J. Wechalekar, Ashutosh D. Manisty, Charlotte H. Schelbert, Eric B. Kellman, Peter Gillmore, Julian D. Hawkins, Philip N. Moon, James C. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis |
title | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis |
title_full | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis |
title_fullStr | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis |
title_full_unstemmed | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis |
title_short | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis |
title_sort | prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606985/ https://www.ncbi.nlm.nih.gov/pubmed/26362631 http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016567 |
work_keys_str_mv | AT fontanamarianna prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT picasilvia prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT reantpatricia prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT abdelgadiramna prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT treibelthomasa prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT banypersadsanjaym prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT maestriniviviana prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT barcellawilliam prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT rosministefania prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT bulluckheerajnarain prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT sayedrabyah prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT patelketna prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT mamhoodshameem prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT bucciarelliduccichiara prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT whelancarolj prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT herreyannas prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT lachmannhelenj prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT wechalekarashutoshd prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT manistycharlotteh prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT schelbertericb prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT kellmanpeter prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT gillmorejuliand prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT hawkinsphilipn prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis AT moonjamesc prognosticvalueoflategadoliniumenhancementcardiovascularmagneticresonanceincardiacamyloidosis |